Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin to prevent chronic neuropathic pain after spinal cord trauma
2016-002177-35Phase 3Completed
- Sponsor
- Masaryk University
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gabapentin in Neuralgia and spinal cord injury (SCI) (2 arms), sponsored by Masaryk University. Primary endpoint: Incidence of chronic neuropathic pain at 3 months. Started Jan 2017; status: completed.
02
Drugs
gabapentin
03
Conditions
Neuralgiaspinal cord injury (SCI)
Beyond the preview
Go deeper on 2016-002177-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002177-35.